ECD Proteins
SKU: PME101592 Target: PD-L1
Price: 10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00
ECD Proteins
SKU: PME101591 Target: PD-L1
Price: 10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00
ECD Proteins
SKU: PME101706 Target: PD-L1
Price:10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00
Posts found
Dual-Payload ADCs: The Next Big Thing in the ADC Arena
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, [...]
Apr
Popular Targets in the Bispecific ADC Pipeline
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]
Apr
China’s Growing Impact on ADC Development at AACR 2025
The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place [...]
Apr
CD73: A Potential Target in Cancer Immunotherapy
On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]
Oct
HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]
Sep
Research Progress on BCMA-Targeted Therapies in Multiple Myeloma
On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]
Sep
Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]
Jun
Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for [...]
May
Tumor Immune Target – Claudin18.2
Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the [...]
Apr
GPC3, a Popular Target in Liver Cancer Treatment
On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a [...]
Jan